Not Yet Recruiting PHASE4 INTERVENTIONAL 1-arm NCT05814848

A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

A Single-arm Prospective Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma

Sponsor: Changhai Hospital

Conditions Relapsed or Refractory B-cell Lymphoma

Interventions Relmacabtagene Autoleucel Injection

Updated 4 times since 2023 Last updated: Jun 14, 2023 Started: Jun 20, 2023 Primary completion: Mar 31, 2028 Completion: Mar 31, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05814848, this PHASE4 trial focuses on Relapsed or Refractory B-cell Lymphoma and remains actively recruiting participants. Sponsored by Changhai Hospital, it has been updated 4 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE4
Jul 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE4
May 2023 — Jul 2023 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Changhai Hospital

Data source: Changhai Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.